OUR PURPOSE

Our Ambassadors

OUR AMBASSADORS

Let’s Cure ACC, as an international organization dedicated to adrenal cancer, is proud to have more volunteers, the ambassadors, who can also connect with patients in their native languages. Their main role is to help Let’s Cure ACC effectively engage with patients, relatives or local experts, raise awareness, and provide valuable support to those affected by adrenal cancer across different linguistic and cultural backgrounds. As we know, to have somebody to listen and help in your language should be a basic standard for everyone.

To be connected to an ambassador in your language, complete the form! Please note that, sadly, all languages are not offered but we hope to grow and cover more.

If you are interested to join us as an ambassador or know anyone who might be interested, please contact us for all the details. Everybody (patient, caretaker, doctor, nurse…) can join us !

Aarya was born in 2002 in Texas and now lives in California. She’s currently wrapping up her master’s at UCLA and will be starting medical school later this year. In 2024, as an undergraduate at the University of San Francisco, she completed an honors thesis investigating ACC. Since then, she’s had the privilege to support Let’s Cure ACC as a patient ambassador by primarily acting as a science liaison – including writing descriptions for emerging therapies, making guides for new papers, and updating our website’s patient guide.
As an incoming medical student, she hopes to dedicate her career to the study of rare hormone-sensitive cancers and find new ways to advocate for patients facing these diseases.

Charlotte, born in 1971 in New Orleans, Louisiana, USA, is a pharmacist by training and working as a Market Director in Kansas. 
She was diagnosed with ACC in January 1999 and underwent extensive treatment, including mitotane therapy for 4.5 years, 3 surgeries, and 5 separate recurrences. She had been in remission since May 2006. 

In her personal life, she enjoys traveling, cooking, yoga and tennis. 

Marcie is 45 years old and a lifelong educator. Her 3 favorite things are boybands, baking and Broadway shows. She was diagnosed with ACC in November 2021, and deemed to be ’no evidence of disease’ in December 2023 after massive surgery, two years of daily Mitotane and 25 rounds of radiation. Marcie believes in the importance of being your own best health advocate when faced with such a serious diagnosis.

Masaki is an endocrinologist with a clinical and research focus on adrenocortical carcinoma. He has established a dedicated oncological endocrine clinic within a national cancer hospital in Tokyo, where he has been involved in the care of patients with ACC.
In parallel with his clinical work, he is conducting translational research on ACC in both Japan and Germany. As an ambassador, his goal is not only to advance research, but also to listen, connect, and work together with the ACC community. By sharing knowledge and experiences across borders, he believes we can help each person with ACC feel less alone and more empowered in their journey.

Melody was born in 1989 in China, and now lives in Salt Lake City (US). She became an ambassador for LCACC in 2023. At the time, she was a research scientist studying the mechanisms of and potential therapies for ACC. During her work, she was deeply moved by the board members and their personal stories of resilience in the fight against this disease.
As a scientist with experience in both pre-clinical and clinical research, she hopes to leverage my expertise to support and empower more people in their journey against ACC!

我在2023年成为“让我们治愈肾上腺皮质瘤”患者倡导组织的大使。那时我是一名科研人,正在研究肾上腺皮质瘤的机制和疗法。在工作过程中,我接触到了LCACC患者倡导组织并且被几位成员以及他们的抗癌故事深深的打动。
作为一名有着多年临床前期以及临床试验经验的科研人员,我希望我的专业可以帮助到更多的人!

Natálie was born in the Czech Republic in 1996 and moved to Slovakia at the age of 13, where she has lived ever since. She graduated from the faculty of law and works as a lawyer, although she is currently on a “short” break due to ongoing medical treatment.

In June 2023, Natália was diagnosed with adrenocortical carcinoma. Following surgery, she completed 4 cycles of chemotherapy and began treatment with mitotane. Unfortunately, this treatment was not successful, as metastatic disease developed one year later. Therefore she underwent another surgery, followed by radiation treatment of some metastases using the CyberKnife. Since January 2025 she is receiving a less commonly used but, in her case, effective combination of immunotherapy with pembrolizumab and lenvatinib. The metastases are shrinking and she continues to fight not just for her but also for other patients.